EtoposidePharmacologyPharmacology, ClinicalAntineoplastic Agents, PhytogenicDrug Screening Assays, AntitumorAntineoplastic AgentsXenograft Model Antitumor AssaysAntineoplastic Combined Chemotherapy ProtocolsCisplatinTopoisomerase II InhibitorsDoxorubicinIfosfamideCell Line, TumorCarcinoma, Small CellDNA Topoisomerases, Type IIAntibiotics, AntineoplasticPodophyllotoxinLeukemia P388Dose-Response Relationship, DrugCyclophosphamideTumor Cells, CulturedDrug Administration ScheduleVincristineLung NeoplasmsAmsacrineMice, NudeNeoplasmsApoptosisCarboplatinCombined Modality TherapyNeoplasms, ExperimentalNeoplasm TransplantationBleomycinDrug SynergismSarcoma 180Melanoma, ExperimentalLeukemia L1210CytarabineDrug Resistance, NeoplasmAdministration, OralCamptothecinDrug EvaluationMice, Inbred BALB CCell SurvivalTeniposideTreatment OutcomeGerminomaCancer VaccinesInfusions, IntravenousTopoisomerase I InhibitorsAntigens, NeoplasmLeukopeniaPaclitaxelMice, Inbred C57BLInhibitory Concentration 50Topoisomerase InhibitorsMitoxantroneDrug ResistanceImmunotherapyNucleic Acid Synthesis InhibitorsCell ProliferationDNA DamageTopotecanTransplantation, AutologousRemission InductionTime FactorsCarmustineTesticular NeoplasmsProdrugsDrug Evaluation, PreclinicalSurvival AnalysisOrganophosphorus CompoundsHodgkin DiseaseMice, SCIDImmunotherapy, AdoptiveEnzyme InhibitorsNeoplasms, Germ Cell and EmbryonalSurvival RateTransplantation, HeterologousRazoxaneMolecular StructureAntibodies, MonoclonalLymphoma, Non-HodgkinDisease-Free SurvivalNeutropeniaHematologic DiseasesP-GlycoproteinCell LineEnediynesThrombocytopeniaSalvage TherapyDaunorubicinDrug Resistance, MultipleVinblastineHL-60 CellsCell CycleHalf-LifeCell DivisionColonic NeoplasmsAntineoplastic Agents, Alkylating